SCNI News and Press, Scanner Technologies Corp

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservic...

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb PR Newswire Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the Paul Erlich Institute (the PEI) for its...

A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...

2024-07-15 12:31:08 ET Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis. The biotechnology firm’s shares experienced a significa...

2024-07-15 11:08:35 ET More on Scinai Immunotherapeutics Financial information for Scinai Immunotherapeutics Read the full article on Seeking Alpha For further details see: Scinai stock soars 54% on preclinical study for psoriasis drug

A look at the top 10 most actives in the United States American Rebel Holdings Inc. (AREB) rose 60.3% to $0.83355 on volume of 56,112,820 shares DatChat Inc. (DATS) rose 71.2% to $1.78 on volume of 33,845,116 shares Autonomix Medical Inc. (AMIX) rose 97.4% to $1.22 on volume of 33,054,234...

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model PR Newswire JERUSALEM , July 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company f...

Prostate cancer is challenging to treat, especially when the disease progresses to a castrate-resistant metastatic state. Conventional treatments, such as hormonal treatments, radiotherapy and chemotherapy, fail most times because of acquired resistance, off-target effects and toxicities. It...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced its receipt of an updated non-binding let...